You are here:
Direct Healthcare Professional Communication (DHPC) on Fosfuro® 3000 mg granules for oral solution (fosfomycin trometamol): Deletion of the indication perioperative antibiotic prophylaxis for transrectal prostate biopsy in adult men
2022.05.20
Active substance: fosfomycin trometamol
Apogepha Arzneimittel GmbH as the marketing authorisation holder of Fosfuro® 3000 mg informs in agreement with the Federal Institute for Drugs and Medical Devices (BfArM) that Fosfuro® 3000 mg (fosfomycin trometamol) is not authorised in the indication perioperative antibiotic prophylaxis in transrectal prostate biopsy in adult men and should not be used.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN